戊二酰辅酶A脱氢酶抑制肝细胞癌进展并塑造抗肿瘤微环境
研究纳入三组分别含40、248和17对样本的队列,评估戊二酰辅酶A脱氢酶(GCDH)表达与肝细胞癌(HCC)临床特征及抗PD-1治疗反应的关系,并用皮下、原位异种移植及基因驱动小鼠模型验证。GCDH通过巴豆酰化抑制磷酸戊糖途径和糖酵解,诱导HCC细胞衰老并经SASP塑造抗肿瘤微环境;GCDH低表达人群PD-1+CD8+ T细胞增多,对anti-PD-1治疗更敏感。
要点
- GCDH耗竭促进HCC生长和转移,过表达则逆转这些过程。
- GCDH通过巴豆酰化抑制磷酸戊糖途径和糖酵解,诱导HCC细胞衰老。
- GCDH低表达人群PD-1+CD8+ T细胞增多,对anti-PD-1治疗更敏感。
核心结论
- GCDH通过巴豆酰化诱导抑制磷酸戊糖途径和糖酵解,导致HCC细胞衰老,衰老细胞经SASP塑造抗肿瘤微环境。
- GCDH低表达人群因PD-1+CD8+ T细胞增多而对anti-PD-1治疗更敏感。
研究设计与样本
- 采用三组分别含40、248和17对样本的队列评估GCDH表达与HCC临床特征及抗PD-1治疗反应的关系。
- 采用皮下异种移植、原位异种移植、Trp53Δhep/Δhep; MYC-和Ctnnboe; METoe驱动小鼠模型验证GCDH对HCC的抑制作用。
主要发现
- GCDH耗竭促进HCC生长和转移,而其过表达逆转这些过程。
- GCDH将戊二酰辅酶A转化为巴豆酰辅酶A以提高巴豆酰化水平,巴豆酰化靶点PGD、TKT和ALDOC的酶活性受变构效应调控,导致核糖5-磷酸和乳酸生成减少,限制Warburg效应。
- 磷酸戊糖途径阻断刺激过氧化,与衰老调节剂协同诱导GCDH高表达细胞衰老,这些细胞通过SASP诱导免疫细胞浸润以塑造抗肿瘤免疫微环境。
- GCDH低表达人群对anti-PD-1治疗敏感,因PD-1+CD8+ T细胞增多。
关键数值与推荐
- GCDH是肝、肺和肾癌的有利预后指标。
- GCDH低表达与高表达HCC人群可基于血清葡萄糖和氨水平区分。
临床怎么用
- 作者认为,鉴于GCDH低表达和高表达HCC人群可基于血清葡萄糖和氨水平区分,基于GCDH表达水平评估促衰老和免疫治疗策略的疗效值得进行。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Crotonylation, a crotonyl-CoA-based non-enzymatic protein translational modification, affects diverse biological processes, such as spermatogenesis, tissue injury, inflammation, and neuropsychiatric diseases. Crotonylation is decreased in hepatocellular carcinomas (HCCs), but the mechanism remains unknown. In this study, we aim to describe the role of glutaryl-CoA dehydrogenase (GCDH) in tumor suppression. METHODS: Three cohorts containing 40, 248 and 17 pairs of samples were used to evaluate the link between GCDH expression levels and clinical characteristics of HCC, as well as responses to anti-programmed cell death protein 1 (PD-1) treatment. Subcutaneous xenograft, orthotopic xenograft, Trp53Δhep/Δhep; MYC- and Ctnnboe; METoe-driven mouse models were adopted to validate the effects of GCDH on HCC suppression. RESULTS: GCDH depletion promoted HCC growth and metastasis, whereas its overexpression reversed these processes. As GCDH converts glutaryl-CoA to crotonyl-CoA to increase crotonylation levels, we performed lysine crotonylome analysis and identified the pentose phosphate pathway (PPP) and glycolysis-related proteins PGD, TKT, and ALDOC as GCDH-induced crotonylation targets. Crotonyl-bound targets showed allosteric effects that controlled their enzymatic activities, leading to decreases in ribose 5-phosphate and lactate production, further limiting the Warburg effect. PPP blockade also stimulated peroxidation, synergizing with senescent modulators to induce senescence in GCDHhigh cells. These cells induced the infiltration of immune cells by the SASP (senescence-associated secretory cell phenotype) to shape an anti-tumor immune microenvironment. Meanwhile, the GCDHlow population was sensitized to anti-PD-1 therapy. CONCLUSION: GCDH inhibits HCC progression via crotonylation-induced suppression of the PPP and glycolysis, resulting in HCC cell senescence. The senescent cell further shapes an anti-tumor microenvironment via the SASP. The GCDHlow population is responsive to anti-PD-1 therapy because of the increased presence of PD-1+CD8+ T cells. IMPACT AND IMPLICATIONS: Glutaryl-CoA dehydrogenase (GCDH) is a favorable prognostic indicator in liver, lung, and renal cancers. In addition, most GCDH depletion-induced toxic metabolites originate from the liver, accumulate locally, and cannot cross the blood-brain barrier. Herein, we show that GCDH inhibits hepatocellular carcinoma (HCC) progression via crotonylation-induced suppression of the pentose phosphate pathway and glycolysis, resulting in HCC cell senescence. We also found that more PD-1+CD8+ T cells are present in the GCDHlow population, who are thus more responsive to anti-PD-1 therapy. Given that the GCDHlow and GCDHhigh HCC population can be distinguished based on serum glucose and ammonia levels, it will be worthwhile to evaluate the curative effects of pro-senescent and immune-therapeutic strategies based on the expression levels of GCDH.
引用
- Lao Y, Cui X, Xu Z, et al. Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma. J Hepatol. 2024. PMID: 38825017. doi:10.1016/j.jhep.2024.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。